<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The efficacy and safety of topotecan and high-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> were evaluated in 59 patients with advanced <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (n = 38) or <z:hpo ids='HP_0011010'>chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) (n = 21) </plain></SENT>
<SENT sid="1" pm="."><plain>Topotecan 1.25 mg/m2/d was administered by continuous Intravenous infusion daily for 5 days, and <z:chebi fb="0" ids="28680">cytarabine</z:chebi> 1.0g/m2/d by Infusion over 2 hours for 5 days </plain></SENT>
<SENT sid="2" pm="."><plain>At a median follow-up duration of 7 months, 59 patients were evaluable for response and toxicity </plain></SENT>
<SENT sid="3" pm="."><plain>Complete remission (CR) was achieved in a significantly larger proportion of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients than <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients (66% v 48%, P &lt; or = .05) </plain></SENT>
<SENT sid="4" pm="."><plain>CR rates for good-risk and poor-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were similar (79% and 58%, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment was particularly effective in patients with poor-prognosis karyotypes and <z:e sem="disease" ids="C0280745" disease_type="Neoplastic Process" abbrv="">secondary MDS</z:e>, producing CR rates of 63% and 69%, respectively </plain></SENT>
<SENT sid="6" pm="."><plain>Medlan duration of CR was 32 weeks (41 weeks for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 33 weeks for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) </plain></SENT>
<SENT sid="7" pm="."><plain>Median survival was 60 weeks for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and 41 weeks for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain>Prospective analysis of response by International Prognostic Scoring System (IPSS) risk classification showed comparable CR rates among intermediate 1 (60%), Intermediate 2 (83%), and high-risk (56%) categories </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0001945'>Fever</z:hpo> of undetermined origin and <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">Infections</z:e> occurred in 72% and 59% of patients, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>Six patients (10%) died during Induction therapy </plain></SENT>
<SENT sid="11" pm="."><plain>This regimen was well tolerated and was associated with a low mortality rate </plain></SENT>
</text></document>